Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms

被引:2
|
作者
Keski, Hakan [1 ]
机构
[1] Kocaeli Univ, Dept Internal Med, Div Hematol, Kocaeli, Turkey
关键词
Bone marrow fibrosis; CD34; Mast cell; Myeloproliferative neoplasm; Reticulin fiber; PERIPHERAL-BLOOD; ESSENTIAL THROMBOCYTHEMIA; EUROPEAN CONSENSUS; CD34(+) CELLS; MYELOFIBROSIS; NUMBER; CLASSIFICATION; MASTOCYTOSIS; PROGNOSIS; IMPACT;
D O I
10.1016/j.bcmd.2020.102420
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We aimed to investigate the association of bone marrow mast cell numbers (MCN) and the degree of reticulin fibrosis in patients with chronic myeloproliferative neoplasms (MPN). Methods: This was a case-control study that recruited 47 patients who were diagnosed with bcr-abl negative MPN. Thirty patients with lymphoma served as controls. JAK2 mutation was studied and all subjects underwent bone marrow biopsy at the time of diagnosis. Mast and CD34 + cells were counted. Marrow reticulin fiber was graded. Results: Thirty-four patients had essential thrombocythemia (ET), 8 patients had primary myelofibrosis (PMF) and 5 patients had polycythemia vera (PV). Fourteen MPN patients had JAK2, whereas the controls had not. MCN was higher in patients than controls (p = 0.001). There was no significant difference regarding CD34. Reticulin fibrosis was present in 57.4% of MPN patients, whereas there was any in controls. PMF patients had more CD34 + cells than PV and ET. PMF patients had more reticulin fibers compared with other subgroups (p < 0.001). MCN, but not CD34 + cell counts, was significantly higher in JAK2( + ) patients than JAK2( - ) patients. Conclusion: MCN and reticulin fibrosis were significantly increased in MPN patients. JAK2 positivity had significantly increased MCN compared to patients without JAK2. JAK2 was associated with increased reticulin fibrosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] BCR-ABL negative myeloproliferative neoplasms
    Metzgeroth, G.
    Lengfelder, E.
    Griesshammer, M.
    Reiter, A.
    ONKOLOGE, 2012, 18 (12): : 1130 - +
  • [2] Thiol/Disulfide Balance in Older Patients with BCR-ABL Negative Myeloproliferative Neoplasms
    Koyuncu, Mahmut B.
    Cavusoglu, Cagatay
    Basir, Hakan
    Ilgan, Mustafa
    Ucar, Mehmet A.
    Akdeniz, Aydan
    Tombak, Anil
    Tiftik, Eyup N.
    Temel, Gulhan O.
    Neselioglu, Salim
    Erel, Ozcan
    CLINICAL LABORATORY, 2021, 67 (12) : 2700 - 2706
  • [3] Screening for signs of portal hypertension by esophagogastroduodenoscopy in patients with BCR-ABL negative myeloproliferative neoplasms
    Davidson, Marta
    Wong, Florence
    Atri, Mostafa
    Sibai, Hassan
    Maze, Dawn
    Cheung, Verna
    Callum, Jeannie
    Atenafu, Eshetu G.
    Gupta, Vikas
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : E88 - E90
  • [4] Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL -Negative Myeloproliferative Neoplasms
    Wille, Kai
    Deventer, Eva
    Sadjadian, Parvis
    Becker, Tatjana
    Kolatzki, Vera
    Huenerbein, Karlo
    Meixner, Raphael
    Jimenez-Munoz, Marina
    Fuchs, Christiane
    Griesshammer, Martin
    HAMOSTASEOLOGIE, 2024, 44 (05): : 386 - 392
  • [5] High rate of secondary primary malignancies in patients with BCR-ABL negative myeloproliferative neoplasms
    Wille, K.
    Sadjadian, P.
    Becker, T.
    Horstmann, A.
    Kolatzki, V
    Griesshammer, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 28 - 28
  • [6] Recent advances in the bcr-abl negative chronic myeloproliferative diseases
    Michael Bennett
    David F Stroncek
    Journal of Translational Medicine, 4
  • [7] Recent advances in the bcr-abl negative chronic myeloproliferative diseases
    Bennett, Michael
    Stroncek, David F.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)
  • [8] Therapeutic potential of Axl blockade in BCR-ABL negative myeloproliferative neoplasms (MPN)
    Beitzen-Heineke, A.
    Ben Batalla, I
    Paesler, S.
    Gensch, V
    Schafhausen, P.
    von Amsberg, G.
    Riecken, K.
    Fischer, T.
    Pantel, K.
    Bokemeyer, C.
    Loges, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 27 - 27
  • [9] Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)
    Beitzen-Heineke, Antonia
    Ben Batalla, Isabel
    Berenbrok, Nikolaus
    Paesler, Sarina
    Gensch, Victoria
    von Amsberg, Gunhild
    Schafhausen, Philippe
    Riecken, Kristoffer
    Fischer, Thomas
    Pantel, Klaus
    Bokemeyer, Carsten
    Loges, Sonja
    BLOOD, 2018, 132
  • [10] Evaluation of hMICL As a Marker Associated with Disease Progression in BCR-ABL Negative Myeloproliferative Neoplasms
    Nederby, Line
    Larsen, Laura Laine
    Hokland, Peter
    Roug, Anne Stidsholt
    BLOOD, 2012, 120 (21)